CML Partnership 091012c

Article

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.

If you do not wish to leave this site, click Cancel. Or, click OK to continue.

Cancel

OK >

Treatment of Ph+ CML

Advancing Science

Advancing Care

Future goals for Ph+ CML patients are being shaped by an actively evolving paradigm.

Stay up to date with these interactive assets.

Explore the evolution
of Ph+ CML care

Find out more about early
therapies, important milestones,
and the new era of advanced care

Learn more >

A guide to read and interpret IS RQ-PCR reports

Learn how IS RQ-PCR results track progress and inform treatment decisions

The importance of the International Scale for RQ-PCR

A deeper look at why the International Scale is used to standardize results

Watch a new video on Ph+ CML care

The mechanism of the disease provides a crucial learning for treating Ph+ CML

  • Learn More >

Maecenas non auctor est. Aliquam erat

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

  • Learn More >

Proin egestas tellus sit amet mi

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

  • Learn More >

Curabitur nisi est, consectetur eu mollis

Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.

  • Learn More >

For information about a free trial of IS RQ-PCR, call MolecularMD at 877-459-4979 or
Genoptix at 800-755-1605 and ask about GET RQ-PCR NOW.

To learn more about Ph+ CML treatment options, click here.

Glossary

AP=accelerated phase. BC=blast crisis. BCR-ABL=breakpoint cluster region-abelson. Ph+ CML=Philadelphia chromosome-positive chronic myeloid leukemia. CBC=complete blood count. CHR=complete hematologic response. mCyR=major cytogenic response. PCyR=partial cytogenetic response. CCyR=complete cytogenetic response. FISH=fluorescence in situ hybridization. ELN=European Leukemia Net. MMR=major molecular response. MR=molecular response. MRD=minimal residual disease. NCCN=National Comprehensive Cancer Network. IS=International Scale. RQ-PCR=real-time quantitative polymerase chain reaction. TKI=tyrosine kinase inhibitor.

Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080 © 2012 Novartis 08/12 T-CDE-1047709

Related Videos
A panel of 4 experts on breast cancer seated at a long table
Rani Bansal, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
Heather Moore, CPP, PharmD, an expert on breast cancer
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Michael Foote, MD, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Related Content